**Present**: There is a duplication of images within Figure [5F](#F5){ref-type="fig"} and a typing error within Figure [4B](#F4){ref-type="fig"}

**Correct**: The proper figure images are shown below. The authors sincerely apologize for this error.
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![LMK-235 inhibits BC cell proliferation and induces apoptosis\
**B.** MDA-MB-231 and Hs-578T cells were treated with DMSO or 50 nM, 500 nM, or 1 μM LMK-235 for 24 hours. The levels of acetyl-histone H3 and total histone H3 were examined by western blot. GAPDH was used as a loading control.](oncotarget-08-30619-g001){#F4}

![LMK-235 synergizes with bortezomib in BC cells\
**F.** MDA-MB-231 and Hs-578T cells were plated in Matrigel invasion chambers and treated with 200 nM LMK-235 and/or 5 nM bortezomib for 24 hours. Three separate experiments were conducted, and representative results are shown. Magnification, ×100. Columns indicate the average number of invading cells from 5 random microscopic fields. \*p\<0.05 compared with the DMSO group; \*\*p\<0.05 compared with the equivalent doses in the LMK-235- or bortezomib-treated groups.](oncotarget-08-30619-g002){#F5}
